The results of this nested case–control study in the CPRD indicate no evidence for a higher risk of MI or cardiovascular death associated with the use of strontium ranelate

in women treated for osteoporosis compared with non-use of this agent in routine medical practice in the UK.

Autor: C. Cooper, K. M. Fox, J. S. Borer

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • 15 − dos =